Uptake of screening and prevention in women at very high risk of breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/82450
Title:
Uptake of screening and prevention in women at very high risk of breast cancer.
Authors:
Evans, D Gareth R; Lalloo, Fiona; Shenton, Andrew; Boggis, C; Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Management of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10% of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.
Citation:
Uptake of screening and prevention in women at very high risk of breast cancer. 2001, 358 (9285):889-90 Lancet
Journal:
Lancet
Issue Date:
15-Sep-2001
URI:
http://hdl.handle.net/10541/82450
DOI:
10.1016/S0140-6736(01)06039-1
PubMed ID:
11567707
Type:
Article
Language:
en
ISSN:
0140-6736
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorEvans, D Gareth R-
dc.contributor.authorLalloo, Fiona-
dc.contributor.authorShenton, Andrew-
dc.contributor.authorBoggis, C-
dc.contributor.authorHowell, Anthony-
dc.date.accessioned2009-09-24T11:10:36Z-
dc.date.available2009-09-24T11:10:36Z-
dc.date.issued2001-09-15-
dc.identifier.citationUptake of screening and prevention in women at very high risk of breast cancer. 2001, 358 (9285):889-90 Lanceten
dc.identifier.issn0140-6736-
dc.identifier.pmid11567707-
dc.identifier.doi10.1016/S0140-6736(01)06039-1-
dc.identifier.urihttp://hdl.handle.net/10541/82450-
dc.description.abstractManagement of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10% of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Proteinsen
dc.subject.meshAdult-
dc.subject.meshBRCA2 Protein-
dc.subject.meshBreast Neoplasms-
dc.subject.meshFemale-
dc.subject.meshGenes, BRCA1-
dc.subject.meshHumans-
dc.subject.meshMagnetic Resonance Imaging-
dc.subject.meshMass Screening-
dc.subject.meshMastectomy-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshRisk Factors-
dc.subject.meshTranscription Factors-
dc.titleUptake of screening and prevention in women at very high risk of breast cancer.en
dc.typeArticleen
dc.identifier.journalLanceten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.